The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July, with a decision provisionally expected in September. However, to the disappointment of the Duchenne community, a second committee meeting will now be held in October.

Produced by Italfarmaco, givinostat is taken as an oral suspension twice daily. It is a type of treatment known as an HDAC inhibitor, which reduces muscle in­flammation and fibrosis. HDAC inhibitors also promote muscle regeneration and slow the progression of Duchenne.

Givinostat (also known by its brand name Duvyzat) was approved for market authorisation by UK’s MHRA in December 2024, for those aged 6+.

It was also recommended for approval by the European Medicines Agency (EMA) in April 2025, for those who are aged 6+, ambulant, and who are being treated with steroids.

While NICE has been assessing givinostat, it has been made available for free through the NHS via the Early Access Programme (EAP) – a compassionate use scheme.

Our friends at Duchenne UK launched the Time Is Muscle campaign, to advocate for all eligible clinics to take part in the Early Access Programme. Although givinostat is available in this way, not all patients have been able to access it, often due to the paperwork the clinic must complete to take part. Duchenne UK’s campaign has been raising significant awareness and also empowering families to approach their clinic to discuss access.

Duchenne UK is also engaging with NICE to urge the approval of givinostat, and will be holding a Parliamentary event in September to raise further awareness.

Click here to learn more about Duchenne UK’s campaign.